A business unit of Wilmington-based Pharmaceutical Product Development announced Thursday an agreement to acquire Medimix International, a global technology company that provides insights and information to the pharmaceutical, diagnostic and medical device industries, according to a news release.

The acquisition will allow Maryland-based Evidera -- a business unit of PPD and provider of evidence-based solutions aimed at demonstrating the real-world effectiveness, safety and value of health care products -- to offer customers enhanced technology solutions, real-world data and access to health care providers, stated the release.

PPD, a global contract research organization, acquired Evidera in 2016, according to Evidera's website.

Randy Buckwalter, PPD’s senior manager of corporate communications, said Thursday that the financial terms were not disclosed and no date for the acquisition has been established.

Through Medimix, Evidera President Karen Kaucic said that Evidera will have access to a large pool of global clinician and patient-level information to "enhance client business decisions related to forecasting, marketing, commercial analytics, business intelligence, health economics, medical affairs, strategy and licensing."

Medimix uses a panel of about 2.2 million clinicians with a focus on hematology and oncology, according to the release.

"We look forward to leveraging the capabilities and resources of Medimix to develop novel approaches to access and maximize the utility of real-world data," Kaucic said.